Clinical trial
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In…
NCT00239967 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00239967 |
|---|---|
| Title | An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients |
| Official title | A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients |
| Acronym | ADAGIO-lipids |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dyslipidemia, Obesity |
| Intervention type | Drug |
| Interventions | Rimonabant (SR141716), Placebo |
| Enrollment | 803 |
| Start date | May 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Oct 17, 2005 |
| Last update posted | Apr 7, 2009 |
| Countries | Australia, Brazil, Canada, Denmark, Hong Kong, Italy, Malaysia, Mexico, Singapore, South Africa, South Korea, Sweden and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: